Following a prolonged and high-stakes legal battle, the U.S. Food and Drug Administration (FDA) granted Juul marketing ...

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in young children.

All FDA therapeutic approvals from June 2025 across various oncology indications and cancer types. In June of 2025, the U.S. Food and Drug Administration (FDA) approved multiple cancer treatments and ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...

Health officials say smoking has been at a high rate in Eastern Kentucky and e-cigarettes are still considered dangerous.

Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...

Ready-to-Dilute Tepylute in Breast and Ovarian cancer Finally, on April 29, the FDA shared that treatment with 100 milligrams of Tepylute (formerly SH-105) had been approved for breast and ovarian ...

The FDA based its approval on results from the LIBERTY-BP ADEPT (NCT04206553) phase 2 and 3 study, which found dupilumab effective for adults with moderate to severe bullous pemphigoid and met ...

Meanwhile, Thursday's approval came two weeks after the FDA missed its original target decision date for Nucala in COPD. GSK had originally expected to hear a verdict on its filing by May 7.

The FDA has decided not to approve glofitamab plus gemcitabine and oxaliplatin to treat certain patients with relapsed/refractory DLBCL.